Zealand Pharma AS(NASDAQ:ZEAL) stock News

ZEAL Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Zealand Pharma

Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022

3 years ago - By: Zealand Pharma

Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting

3 years ago - By: Zealand Pharma

Total number of shares and voting rights in Zealand Pharma at October 31, 2022

3 years ago - By: Benzinga - Mentions: NVO FMTX

Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes

3 years ago - By: Zealand Pharma

Zealand Pharma major shareholder announcement: Polar Capital

3 years ago - By: Zealand Pharma

Zealand Pharma major shareholder announcement: Van Herk Investments

3 years ago - By: Zealand Pharma

Zealand Pharma completes registration of capital increase

3 years ago - By: Benzinga - Mentions: NVO

Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels

3 years ago - By: Zealand Pharma

Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million

3 years ago - By: Zealand Pharma

Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares

3 years ago - By: Zealand Pharma

Total number of shares and voting rights in Zealand Pharma at September 30, 2022

3 years ago - By: Zealand Pharma

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)

3 years ago - By: Zealand Pharma

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

3 years ago - By: Zealand Pharma

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting

3 years ago - By: Zealand Pharma

Zealand Pharma grants warrants to employees in Denmark

3 years ago - By: Zealand Pharma

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

3 years ago - By: Zealand Pharma

Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

3 years ago - By: Zealand Pharma

Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)

3 years ago - By: Zealand Pharma

Total number of shares and voting rights in Zealand Pharma at August 31, 2022

3 years ago - By: Zealand Pharma

Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer

3 years ago - By: Zealand Pharma

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

3 years ago - By: Zealand Pharma

Zealand Pharma Announces Financial Results for the First Half of 2022

3 years ago - By: Zealand Pharma

Updated notice to holders of ADSs regarding termination of Deposit Agreement

3 years ago - By: Zealand Pharma

Zealand Pharma AS (ZEAL) Stock News

ZEAL Latest News, Press Relases and Analysis

Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022

Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting

Total number of shares and voting rights in Zealand Pharma at October 31, 2022

Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes

Zealand Pharma major shareholder announcement: Polar Capital

Zealand Pharma major shareholder announcement: Van Herk Investments

Zealand Pharma completes registration of capital increase

Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels

Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million

Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares

Total number of shares and voting rights in Zealand Pharma at September 30, 2022

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting

Zealand Pharma grants warrants to employees in Denmark

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)

Total number of shares and voting rights in Zealand Pharma at August 31, 2022

Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Zealand Pharma Announces Financial Results for the First Half of 2022

Updated notice to holders of ADSs regarding termination of Deposit Agreement

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market